Relapsed/refractory diffuse large B-cell lymphoma

JW Friedberg - Hematology 2010, the American Society of …, 2011 - ashpublications.org
Despite overall improvements in outcomes of diffuse large B-cell lymphoma (DLBCL),
approximately one-third of patients will develop relapsed/refractory disease that remains a …

Transformed follicular non-Hodgkin lymphoma

C Casulo, WR Burack… - Blood, The Journal of the …, 2015 - ashpublications.org
Histologic transformation of follicular lymphoma to an aggressive non-Hodgkin lymphoma is
a critical biologic event with profound implications on the natural history of this otherwise …

Diffuse large B-cell lymphoma

JW Friedberg, RI Fisher - Hematology/oncology clinics of North America, 2008 - Elsevier
Patients who have non-Hodgkin's lymphoma or Hodgkin lymphoma most often present for
medical attention because of signs or symptoms referable to enlarged lymph nodes or other …

[HTML][HTML] Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma

SS Neelapu, FL Locke, NL Bartlett… - … England Journal of …, 2017 - Mass Medical Soc
Background In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory …

The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee

E Campo, ES Jaffe, JR Cook… - Blood, The Journal …, 2022 - ashpublications.org
Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …

[HTML][HTML] Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma

H Tilly, F Morschhauser, LH Sehn… - … England Journal of …, 2022 - Mass Medical Soc
Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60 …

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Z Zhou, LH Sehn, AW Rademaker… - Blood, The Journal …, 2014 - ashpublications.org
Abstract The International Prognostic Index (IPI) has been the basis for determining
prognosis in patients with aggressive non-Hodgkin lymphoma (NHL) for the past 20 years …

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

JW Friedberg, J Sharman… - Blood, The Journal …, 2010 - ashpublications.org
Certain malignant B cells rely on B-cell receptor (BCR)–mediated survival signals. Spleen
tyrosine kinase (Syk) initiates and amplifies the BCR signal. In in vivo analyses of B-cell …

[HTML][HTML] Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma

SM Ansell, J Radford, JM Connors… - … England Journal of …, 2022 - Mass Medical Soc
Background Five-year follow-up in a trial involving patients with previously untreated stage
III or IV classic Hodgkin's lymphoma showed long-term progression-free survival benefits …

[HTML][HTML] Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an …

C Casulo, M Byrtek, KL Dawson, X Zhou… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …